Results 171 to 180 of about 35,846 (211)

The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies

Expert Opinion on Drug Safety, 2018
Type 2 diabetes (T2D), a multifactorial and chronic disease, requires in an elevated percentage of patients the association of several antidiabetic drugs to achieve optimal glycemic control. Dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter inhibitors (SGLT2i) are new classes of oral antidiabetic drugs developed over the last ...
María Molina-Vega, Araceli Muñoz-Garach, José C. Fernández-García, Francisco J. Tinahones   +3 more
openaire   +2 more sources

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

DPP-4 inhibitors improve glycemic control by slowing the proteolytic degradation of endogenous incretin hormones. Enhancement of the effects of these hormones leads to increased glucose-dependent insulin secretion by pancreatic β-cells, reduction in glucagon secretion from pancreatic α-cells, and the slowing of gastric emptying ...
Kimberly C. McKeirnan, Nathan Ramsbacher
openaire   +2 more sources

Pharmacoeconomic analysis of DPP-4 inhibitors.

Die Pharmazie, 2014
Dipeptidyl peptidase-4 (DPP-4) inhibitors and other incretin-related drugs have attracted attention as antidiabetic agents, but they are expensive. The Japanese government has adopted a policy of reducing healthcare costs, and medical institutions must provide medical care while considering economic efficiency.
H, Teramachi, H, Ohta, T, Tachi, M, Toyoshima, T, Mizui, C, Goto, T, Tsuchiya   +6 more
openaire   +1 more source

[DPP-4 inhibitors in nephropatics].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
The use of glucose-lowering drugs in advanced stage diabetic nephropathic patients should be done very carefully. Some drugs are contraindicated or not recommended. The same insulin needs a dose reduction to avoid dangerous hypoglycemia. For some years the use of inhibitors of the DDP-4 has been approved in T2DM patients with CKD III and IV stage ...
Annamaria, Bruzzese, Maria, Pasquale, Carmela, Aloisi, Giuseppe, Costantino, Michele, Buemi   +4 more
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly  

DPP-4 Inhibitors

2017
T. Biftu, R. SinhaRoy
openaire   +1 more source

DPP-4 Inhibitors: Monotherapy

2013
Navjot Singh, Jubbin Jacob
openaire   +1 more source

DPP-4 Inhibitors: Combination Therapy

2013
Navjot Singh, Jubbin Jacob
openaire   +1 more source

Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention

Ca-A Cancer Journal for Clinicians, 2017
Cynthia Morata-Tarifa, Joyce M Slingerland   +1 more
exaly  

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

Ca-A Cancer Journal for Clinicians, 2020
Aaron J Grossberg, William L Hwang, Anirban Maitra   +2 more
exaly